These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2700 related articles for article (PubMed ID: 27582220)

  • 1. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
    Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
    Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
    Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
    Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
    Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.
    Bastrup J; Hansen KH; Poulsen TBG; Kastaniegaard K; Asuni AA; Christensen S; Belling D; Helboe L; Stensballe A; Volbracht C
    J Alzheimers Dis; 2021; 79(1):249-265. PubMed ID: 33252074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.
    Toda Y; Iwatsubo T; Nakamura Y; Matsuda N; Miyata M; Jin M; Chen T; Kuribayashi K; Tian Y; Hughes R; Yamamoto J; Muralidharan KK; Rubel C; Hutchison RM; Budd Haeberlein S
    J Prev Alzheimers Dis; 2024; 11(5):1260-1269. PubMed ID: 39350371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease.
    Leinenga G; Koh WK; Götz J
    Alzheimers Res Ther; 2021 Apr; 13(1):76. PubMed ID: 33836798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
    Brody DL; Jiang H; Wildburger N; Esparza TJ
    Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer's disease.
    Park S; Kim HY; Oh HA; Shin J; Park IW; Yoon S; Woo DH; Kim Y
    Sci Rep; 2021 Jun; 11(1):12043. PubMed ID: 34103615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
    Gamage KK; Kumar S
    J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
    [No Abstract]   [Full Text] [Related]  

  • 15. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
    Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
    N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
    Yang F; Lim GP; Begum AN; Ubeda OJ; Simmons MR; Ambegaokar SS; Chen PP; Kayed R; Glabe CG; Frautschy SA; Cole GM
    J Biol Chem; 2005 Feb; 280(7):5892-901. PubMed ID: 15590663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation.
    Frost CV; Zacharias M
    Proteins; 2020 Dec; 88(12):1592-1606. PubMed ID: 32666627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
    Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
    J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models.
    Balducci C; Mancini S; Minniti S; La Vitola P; Zotti M; Sancini G; Mauri M; Cagnotto A; Colombo L; Fiordaliso F; Grigoli E; Salmona M; Snellman A; Haaparanta-Solin M; Forloni G; Masserini M; Re F
    J Neurosci; 2014 Oct; 34(42):14022-31. PubMed ID: 25319699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 135.